FASN and Wilson disease: In the WD/CCl4 murine model, the chronic treatment of PTM (10 mg/kg) for 13 weeks significantly reduced the protein level of FASN in the livers of treated mice, corroborating attenuated liver steatosis and reduced TG in their livers and plasma (Figure 2 and Figure S2).